James E. Neffendorf
Papers
1
Total Citations
12
H-Index
1
About
James E. Neffendorf is a leading ophthalmology researcher whose work centers on neovascular age-related macular degeneration (nAMD), a primary cause of blindness, and the development of novel therapeutic strategies to reduce treatment burden. His most significant contribution is his pivotal role in the STAR trial (2024), a landmark randomized, double-masked, sham-controlled study evaluating stereotactic radiotherapy for nAMD. This work demonstrated that ionizing radiation can mitigate key pathogenic processes, offering a potential alternative to frequent anti-VEGF injections. With 12 citations, this trial has already shaped clinical discussions around combining radiation with standard care to extend treatment intervals. Neffendorf’s research addresses a critical unmet need—improving patient compliance and quality of life by reducing injection frequency. His achievements include advancing the evidence base for non-invasive adjunctive therapies, positioning him as a key figure in translational ophthalmology. For students and researchers, his work exemplifies how rigorous trial design can challenge established paradigms, offering hope for more durable, less invasive solutions in retinal disease management.
Research Focus
Key Achievements
Top Papers
- 1